DFDA

Levothyroxine + Liothyronine (Combination Therapy)

Treatment for Hashimotos Thyroiditis

Typical Dosage: LT4: 50-200 mcg, LT3: 5-25 mcg daily

Effectiveness
85%
Safety Score
60%
Clinical Trials
50
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠ī¸
Meth💀
CigarettesđŸšŦ
Chemoâ˜ĸī¸
AlcoholđŸē
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
LT4: 50-200 mcg, LT3: 5-25 mcg daily
Time to Effect
4-8 weeks
Treatment Duration
lifetime
Evidence Quality
MODERATE
Confidence Score
65%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$430
Monitoring:$250
Side Effect Mgmt:$100
Total Annual:$780
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$867
Cost per Remission
$867
Comparison vs Levothyroxine monotherapy
Cost Difference
+$500/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Levothyroxine + Liothyronine (Combination Therapy) Outcomes

for Hashimotos Thyroiditis

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+90%
Remission Rate
+90%
Common Side Effects
Hyperthyroid symptoms (e.g., palpitations, anxiety)
+15%
Arrhythmias (rare, higher risk than LT4)
+0.5%

Sources:

wikipedia.org
sbu.se
utppublishing.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov